Top 5 Drug Type | Count |
---|---|
Proteolysis-targeting chimeras (PROTAC) | 17 |
Small molecule drug | 15 |
Fusion protein | 4 |
Chemical drugs | 2 |
Synthetic peptide | 1 |
Target |
Mechanism micro-dystrophin stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism secretin antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date30 Nov 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Adenosine inhibitors(Texas A&M University) ( Adenosine ) | Mycobacterium Tuberculosis, Susceptibility to Infection By More | Preclinical |
RTI-79 | Neoplasms More | Preclinical |
pal-pom-2 ( CDK4 x CDK6 ) | Neoplasms More | Preclinical |
EZ-120 ( Mycobacterial antigen complex 85 x Mycolic acid synthase ) | Tuberculosis More | Preclinical |
Peptide Lv ( VEGFR2 ) | Atherosclerosis More | Preclinical |